Drug intelligence / Profile preview

ARB1035

Development stage: Preclinical
Lead developer: Arbele
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ARB1035 is a biparatopic antibody-drug conjugate (ADC) being developed by Arbele for the treatment of CDH17-positive tumors. It targets cadherin-17 (CDH17), a protein overexpressed in certain cancers, and delivers a cytotoxic payload to tumor cells expressing this marker. The drug uses monomethyl auristatin E (MMAE) as its cytotoxic agent. As of early 2025, ARB1035 is in preclinical development for cancer indications[1][2][3].

Targets

CDH17 (Cadherin-17)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ARB1035.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARB1035.

Explore the full profile